Walmsley, a director at Akero Therapeutics ... The shares are primarily held through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where Walmsley is a managing member of the ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

Akero Therapeutics, Inc. (NASDAQ ... Post-transaction, Walmsley holds an indirect ownership of 1,000,000 shares, primarily through Logos Global Master Fund LP and Logos Opportunities Fund IV LP.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc.

Akero Therapeutics (AKRO) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. All of the shares in the proposed offering are being offered by ...

Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.

The Akero statement underlined how well their medicine efruxifermin treats compensated cirrhosis brought on by metabolic dysfunction-associated steatohepatitis. Akero claims that compared to 15 ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports.

Treatment with an experimental drug from Akero Therapeutics substantially reversed liver damage in a mid-stage study of people with cirrhosis due to metabolic dysfunction-associated ...

Akero Therapeutics Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX ...